Research has found that in patients with MS (especially relapse–release-type MS, RRMS), the concentration of UCHL1 in the plasma is significantly higher than that in the healthy control group, indicating that UCHL1 may serve as a sensitive biomarker for the diagnosis of RRMS [48]. The gene discussed is UCHL1; the disease is myeloid sarcoma.